Home » Topics » Regulatory » EMA

EMA
RSS

Merck Serono Europe withdraws MAA for Movectro

Feb. 21, 2011

European orphan drug status recommended for QLT-091001 in LCA and RP

Feb. 11, 2011

Johnson & Johnson reports highlights fourth quarter 2010

Feb. 9, 2011

EMA grants orphan drug status to GT-038 in retinitis pigmentosa

Feb. 9, 2011

FluEnz approved in E.U. for prevention of seasonal flu in children

Feb. 7, 2011

EMA approves sublingual sildenafil formulation X-Excite for erectile dysfunction

Feb. 3, 2011

EMA confirms eligibility of Omeros' OMS-103HP for centralized marketing application

Feb. 2, 2011

Onyx initiates rolling NDA for carfilzomib in multiple myeloma

Feb. 1, 2011

CHMP recommends approval of BF-200 ALA for actinic keratosis

Feb. 1, 2011

Regadenoson approved in E.U. as an aid to diagnose CAD

Jan. 28, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 15, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...